Poniard Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PARD research report →
About the company
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers.
- CEO
- Robert F. Caspari
- IPO
- 1988
- Employees
- 7
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $150
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -187.25%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-30,051,000 · 34.26%
- EPS
- $-26.40 · 49.62%
- Op Income
- $-27,958,000
- FCF YoY
- 31.62%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -36.63
- Avg Volume
- 46
Get TickerSpark's AI analysis on PARD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 27, 12 | PERRY MICHAEL S | sell | 1,599 |
| Mar 26, 12 | PERRY MICHAEL S | other | 2,800 |
| Mar 26, 12 | PERRY MICHAEL S | other | 2,800 |
| Feb 16, 12 | PERRY MICHAEL S | sell | 6,346 |
| Feb 15, 12 | PERRY MICHAEL S | other | 12,019 |
| Feb 15, 12 | PERRY MICHAEL S | other | 12,019 |
| Oct 6, 11 | MARTELL RON | other | 25,000 |
| Oct 6, 11 | MARTELL RON | other | 25,000 |
| Jul 11, 11 | LYONS GARY A | other | 85,000 |
| Jul 11, 11 | LYONS GARY A | other | 85,000 |
Our PARD coverage
Recent articles, reports, and earnings notes.
No research on PARD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PARD report →Similar companies
Peers in the same neighborhood.